Analytical insights: Reviewing established methods for ambroxol hydrochloride, levosalbutamol sulphate, and guaiphenesin

One important area of over-the-counter (OTC) medicine is the cough and cold segment. Traditional cough
and cold remedies are available over-the-counter (OTC), but the market is strongly competitive. Ambroxol,
levosalbutamol, and guaifenesin are ingredients in pulmoclear LS syrup, a medication classed as a mucolytic,
bronchodilator, and expectorant. It is recommended for use in the treatment of mucus-producing productive
cough in adults and also in children older than six years, who have bronchospasm, a condition in which the
lung muscles spasm and cause difficulty breathing. Extreme respiratory diseases such as chronic obstructive
pulmonary disease, cystic fibrosis, and asthma are characterized by increased mucus secretion.
Levosalbutamol sulphate, ambroxol hydrochloride, and guaiphenesin work well together to treat asthmatic
bronchoconstriction, productive and unproductive cough, common cold, and respiratory tract diseases.
Ambroxol is a mucolytic agent that increases the volume of mucus while decreasing its viscosity to aid in
its clearance. It eases productive coughing and helps with expectoration. An expectorant called guaiphenesin
helps people spit out mucus by making lung secretions less viscous. Levosalbutamol is a beta-agonist that
acts as an anti-inflammatory and helps to relax smooth muscles by activating the beta-2 adrenergic
receptors in the lungs. This opens the airways for easier breathing. When combined, they assist patients
with congestion in breathing deeply and freely.
The purpose of this article is to review the development and validation of analytical methods for the
drugs ambroxol hydrochloride, guaiphenesin, and levosalbutamol sulphate in the pharmaceutical dosage
form.